4551 TORII PHARMACEUTICAL CO., LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4551

TSE Prime

TORII PHARMACEUTICAL CO., LTD.

4,405

JPY

(+0.11%)

Dec 23, 3:30 pm JST

28.12

USD

Dec 23, 1:30 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2020	41,700	4,738	4,971	3,495	124.5	48	Feb 4, 2021	J-GAAP
Dec, 2021	46,987	4,656	4,847	3,374	120.1	48	Feb 10, 2022	J-GAAP
Dec, 2022	48,896	5,540	5,537	3,944	140.4	100	Feb 10, 2023	J-GAAP
Dec, 2023	54,638	5,035	5,307	4,119	146.6	120	Feb 9, 2024	J-GAAP
Dec, 2024 Guidance	61,200	6,700	6,800	5,100	181.4	120	Oct 31, 2024	J-GAAP
YoY	+12.0%	+33.1%	+28.1%	+23.8%	+23.8%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2019	Feb 6, 2019	38,000	-3,200	-3,100	22,500	48	J-GAAP
	Jul 31, 2019	40,800	-700	-400	24,700	48	J-GAAP
	Oct 31, 2019	42,700	700	1,000	25,700	48	J-GAAP
	Jan 20, 2020	42,990	1,430	1,690	27,360	48	J-GAAP
Results	Feb 6, 2020	42,998	1,430	1,691	27,367	48	J-GAAP
Dec, 2020	Feb 6, 2020	Available in future release
	Jul 31, 2020
	Oct 30, 2020
Results	Feb 4, 2021
Dec, 2021	Feb 4, 2021
	Jul 30, 2021
	Oct 29, 2021
Results	Feb 10, 2022
Dec, 2022	Feb 10, 2022
	Jul 29, 2022
	Oct 31, 2022
Results	Feb 10, 2023
Dec, 2023	Feb 10, 2023
	Jul 31, 2023
	Oct 31, 2023
Results	Feb 9, 2024
Dec, 2024	Feb 9, 2024	58,600	5,800	6,200	4,700	120	J-GAAP
	Jul 31, 2024	60,700	6,300	6,400	4,800	120	J-GAAP
	Oct 31, 2024	61,200	6,700	6,800	5,100	120	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2000	45,092	+11.7	Available in future release
Mar, 2001	47,782	+6.0
Mar, 2002	45,928	-3.9
Mar, 2003	43,245	-5.8
Mar, 2004	42,384	-2.0
Mar, 2005	41,908	-1.1
Mar, 2006	40,477	-3.4
Mar, 2007	39,576	-2.2
Mar, 2008	40,845	+3.2
Mar, 2009	37,349	-8.6
Mar, 2010	42,416	+13.6
Mar, 2011	45,335	+6.9
Mar, 2012	48,717	+7.5
Mar, 2013	52,294	+7.3
Mar, 2014	58,109	+11.1
Dec, 2014 Changed	43,504	－
Dec, 2015	62,378	+43.4
Dec, 2016	60,206	-3.5
Dec, 2017	64,135	+6.5
Dec, 2018	62,551	-2.5
Dec, 2019	42,998	-31.3
Dec, 2020	41,700	-3.0
Dec, 2021	46,987	+12.7
Dec, 2022	48,896	+4.1
Dec, 2023	54,638	+11.7
Dec, 2024 Guidance	61,200	+12.0	6,700	+33.1	6,800	+28.1	181.4	+23.7

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2022	48,896	5,540	11.3	3.34	2.98	0.37	140.4
Dec, 2023	54,638	5,035	9.22	3.44	3.08	0.41	146.6
Dec, 2024 Guidance	61,200	6,700	11.0	4.25	3.79	0.45	181.4

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	64,135	13,348	13,504	27,367	975.0
Fiscal Year	Dec, 2017	Mar, 2001	Mar, 2001	Dec, 2019	Dec, 2019

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2021	25,432	2,868	2,996	2,130	75.8	24	Feb 10, 2022	J-GAAP
Jul - Dec, 2022	25,794	2,858	3,069	2,099	74.7	76	Feb 10, 2023	J-GAAP
Jul - Dec, 2023	28,939	3,525	3,764	3,033	108.0	70	Feb 9, 2024	J-GAAP
Jul - Dec, 2024 Guidance	32,891	3,559	3,815	2,879	102.4	60	Oct 31, 2024	J-GAAP
YoY	+13.7%	+1.0%	+1.4%	-5.1%	-5.1%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2021	4,656	-1,654	-156	-1,498	-1,546	58,374	44.63	J-GAAP
Dec, 2022	5,540	-11,256	2,420	-13,676	-1,698	45,420	33.97	J-GAAP
Dec, 2023	5,035	-6,902	-3,123	-3,779	-3,835	34,681	25.99	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2022	35,315	4,066	3,918	2,856	101.7	70.8	Oct 31, 2022	J-GAAP
Jan - Sep, 2023	39,132	3,211	3,315	2,368	84.3	62.5	Oct 31, 2023	J-GAAP
Jan - Sep, 2024	43,333	4,661	4,686	3,525	125.4	68.9	Oct 31, 2024	J-GAAP
YoY	+10.7%	+45.2%	+41.4%	+48.9%	+48.8%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	13,581	1,474	1,619	1,088	38.7	10.9	Feb 10, 2023	J-GAAP
Jan - Mar, 2023	11,811	-437	-404	-288	-10.3	-3.7	Apr 28, 2023	J-GAAP
Apr - Jun, 2023	13,888	1,947	1,947	1,374	48.9	14.0	Jul 31, 2023	J-GAAP
Jul - Sep, 2023	13,433	1,701	1,772	1,282	45.6	12.7	Oct 31, 2023	J-GAAP
Oct - Dec, 2023	15,506	1,824	1,992	1,751	62.3	11.8	Feb 9, 2024	J-GAAP
Jan - Mar, 2024	13,451	1,383	1,166	878	31.3	10.3	Apr 26, 2024	J-GAAP
Apr - Jun, 2024	14,858	1,758	1,819	1,343	47.8	11.8	Jul 31, 2024	J-GAAP
Jul - Sep, 2024	15,024	1,520	1,701	1,304	46.4	10.1	Oct 31, 2024	J-GAAP
YoY	+11.8%	-10.6%	-4.0%	+1.7%	+1.7%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	11,678	-31.3	Available in future release
Jan - Mar, 2020	9,571	+4.5
Apr - Jun, 2020	10,286	-10.7
Jul - Sep, 2020	10,315	-3.0
Oct - Dec, 2020	11,528	-1.3
Jan - Mar, 2021	9,899	+3.4
Apr - Jun, 2021	11,656	+13.3
Jul - Sep, 2021	11,882	+15.2
Oct - Dec, 2021	13,550	+17.5
Jan - Mar, 2022	10,960	+10.7
Apr - Jun, 2022	12,142	+4.2
Jul - Sep, 2022	12,213	+2.8
Oct - Dec, 2022	13,581	+0.2
Jan - Mar, 2023	11,811	+7.8
Apr - Jun, 2023	13,888	+14.4
Jul - Sep, 2023	13,433	+10.0
Oct - Dec, 2023	15,506	+14.2
Jan - Mar, 2024	13,451	+13.9
Apr - Jun, 2024	14,858	+7.0
Jul - Sep, 2024	15,024	+11.8	1,520	-10.6	1,701	-4.0	46.4	+1.8

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	18,409	3,215	5,099	28,522	1,016.4
Fiscal Year	Dec, 2017	Dec, 2003	Dec, 2004	Mar, 2019	Mar, 2019

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2021	4,165.38	89.5	130,810	117,015	106,250	0.00	Feb 10, 2022	J-GAAP
Dec, 2022	4,243.08	89.2	133,689	119,224	108,846	0.00	Feb 10, 2023	J-GAAP
Dec, 2023	4,274.45	90.0	133,432	120,134	109,425	ー	Feb 9, 2024	J-GAAP
Jan - Sep, 2024	ー	89.2	134,612	120,087	109,296	ー	Oct 31, 2024	J-GAAP

TORII PHARMACEUTICAL CO., LTD.(4551) Financial Results